Paul G. Richardson

TL;DR: A retrospective chart review of HCT in patients with multiple myeloma and MRONJ who underwent HCT between December 2005 and December 2014 suggests that patients with MM and MRonJ who undergo HCT are not at increased risk of developing symptoms associated with theMRONJ site or HCT-related infectious complications, and their MRONj is not worsened by HCT.

TL;DR: Biomarker data demonstrated that treatment with everolimus and lenalidomide consistently downregulated protein expression of phosphorylated p70S6K, a downstream target of mTOR, in a heavily pretreated population.

TL;DR: In this paper, the anti-CD38 monoclonal antibody isatuximab was added to pomalidomide and dexamethasone to improve progression-free survival and response rates in patients with relapsed/refractory multiple myeloma.

TL;DR: A post-hoc analysis from a large, well-controlled multicenter phase III trial in frontline MM shows that ESA use did not adversely impact long-term outcomes with VMP or MP, and may be associated with a survival benefit.

TL;DR: A comprehensive review of safety for DF in this setting, including a review of the contribution of DF to observed toxicities in the initial single-arm trials, found that DF was generally well tolerated.